Abstract

You have accessJournal of UrologyBladder Cancer: Detection & Screening1 Apr 2014MP22-16 RECURRENCE RATE OF TRANSURETHRAL RESECTION OF BLADDER TUMOR USING NARROW BAND IMAGING: A RANDOMIZED CONTROL TRIAL, PILOT STUDY Joo Yong Lee, Jae Hyeok Choi, In Kyoung Kim, Hae Do Jung, Ho Won Kang, Ki Soo Lee, Young Eun Yoon, Ji Yong Ha, Kang Su Cho, Joong Shik Lee, In Rae Cho, and Young Deuk Choi Joo Yong LeeJoo Yong Lee More articles by this author , Jae Hyeok ChoiJae Hyeok Choi More articles by this author , In Kyoung KimIn Kyoung Kim More articles by this author , Hae Do JungHae Do Jung More articles by this author , Ho Won KangHo Won Kang More articles by this author , Ki Soo LeeKi Soo Lee More articles by this author , Young Eun YoonYoung Eun Yoon More articles by this author , Ji Yong HaJi Yong Ha More articles by this author , Kang Su ChoKang Su Cho More articles by this author , Joong Shik LeeJoong Shik Lee More articles by this author , In Rae ChoIn Rae Cho More articles by this author , and Young Deuk ChoiYoung Deuk Choi More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2014.02.864AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES The standard non-muscle invasive bladder cancer (NMIBC) endoscopic diagnosis suffers from the frequently unsatisfactory white light imaging (WLI) accuracy leading to residual lesions being left behind. Narrow band imaging (NBI) is an optical image-enhancement technique in which modified optical filters are used in the light source of a video endoscope system. It can enhance the contrast between mucosal and microvascular structures, and distinguish superficial tumors and the normal mucosa. Thus, we evaluated the initial oncological outcomes of transuretheral resection (TUR) for NMIBC. METHODS Consecutive patients with overt or suspected NMIBC were included in a prospective study. Excluding patients with muscle-invasive bladder cancer, negative pathologic examination, or without follow-up, the study population was composed of 68 subjects randomized from Aug, 2010 to Feb, 2013 to NBI with TUR (33 cases) or WLI with TUR (35 cases). Patients’ age, tumor stage, and characteristics including mass size, multiplicity, carcinoma in situ (CIS) and grades were evaluated using Kaplan-Meier analyses. RESULTS Mean patient age was 63.13±12.42 years. Median follow-up (interquartile range; IQR) was 15.57 (9.82-32.10) months. There were no statistical differences in patients’ age (63.82±12.31 years vs. 63.03±12.43 years; p=0.793), and median follow-up periods (16.26 (11.60-20.76) months vs. 15.05 (9.48-32.71) months). In free recurrence analyses using Kaplan-Meier curve, recurrence-free rates were 77.2% (95% CI 61.1-97.7) in NBI group and 73.0% (95% CI 57.2-93.3) in WLI group at 24-months (p=0.416). In subanalyses, high grade (p=0.18), multiple mass (p=0.416), ≥65 years (p=0.696) and <65 years (p=0.525) demonstrated no statistical differences. In patients with CIS, there were no recurrence in NBI group, however, recurrence-free rates were 62.5% (95% CI 36.5-100) at 12 months and 25.0% (95% CI 7.5-83.0) at 24 months in WLI group (p=0.049). CONCLUSIONS TUR performed in the NBI modality reduces the recurrence risk of NMIBC in patients with CIS. © 2014FiguresReferencesRelatedDetails Volume 191Issue 4SApril 2014Page: e240-e241 Advertisement Copyright & Permissions© 2014MetricsAuthor Information Joo Yong Lee More articles by this author Jae Hyeok Choi More articles by this author In Kyoung Kim More articles by this author Hae Do Jung More articles by this author Ho Won Kang More articles by this author Ki Soo Lee More articles by this author Young Eun Yoon More articles by this author Ji Yong Ha More articles by this author Kang Su Cho More articles by this author Joong Shik Lee More articles by this author In Rae Cho More articles by this author Young Deuk Choi More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call